CRC - California Resources Corporation 0 WATCHERS

Why Germany First Matters For A Rerate After The DoctorBox Integration Germany is one of Europe’s largest CRC markets, with about 60,000 new cases a year. Dropping ColoAlert into DoctorBox’s preventive platform puts MYNZ in front of 1,000,000+ users with 10M+ results already delivered and baked-in reminders that nudge people …

DoctorBox Uptake Math: What Would “Real” Look Like In 90 Days DoctorBox lists 1,000,000+ users and 10M+ results. If 1 percent initiated a ColoAlert order in 12 months, that is 10,000 kits. If half of those complete, you are looking at 5,000 completed tests. This is illustrative math, not guidance, …

Digital Integration Is The New Sales Rep: Screening From Reminder To Result DoctorBox does what sales reps cannot. It nudges users with guideline reminders, captures orders at home, routes samples, and delivers results with next steps in one workflow. That reduces friction and can lift adherence. Germany sees roughly 60,000 …

DoctorBox Adds ColoAlert: Real Distribution Inside A 1M User Preventive Platform DoctorBox just added ColoAlert to its portfolio. That is not a vanity partnership. DoctorBox has 1,000,000+ registered users and has processed 10M+ test results, with built-in reminders that nudge people to screen at home. Germany sees roughly 60,000 colorectal …

Europe’s Preventive Funnel Opens For ColoAlert; Three Names Worth A Look The DoctorBox integration puts ColoAlert in front of a large, engaged audience. With 1,000,000+ users and 10M+ results delivered, DoctorBox already guides preventive care with age and risk-based reminders. That can translate to organic demand for MYNZ, which reports …

Policy Tailwinds In Europe Are A Real Demand Engine EU health policy targets higher screening coverage, and colorectal cancer needs it. Roughly 1.9 million cases and about 935,000 deaths occur each year worldwide. Five year survival is near 90 percent when localized and falls to the mid teens when found …

Fed Week Noise Is High; Trade The Calendar You Can Verify Across Names Index timing is messy into rate headlines. I prefer dated catalysts. MYNZ has a feasibility read targeted for 2025 to lock a final CRC panel, then a 2026 pivotal around 15,000 patients and about 150 U.S. sites …

AI Debt Jitters In Tech; In Diagnostics, Let The Data And Delivery Do The Talking AI heavy names are under scrutiny today, so I am focusing on diagnostics with measurable results. MYNZ reports pooled next gen CRC data near 92% sensitivity, 82% advanced adenomas, 95.8% high grade dysplasia, plus pancreas …

Gold Up, Vol Jumpy. Prevention Economics Still Make Sense Safe havens are firmer and volatility is elevated. That does not change the math on screening. Colorectal cancer hits roughly 1.9 million people each year and causes about 935,000 deaths. Five year survival is near 90% when localized and drops to …

Beaten down cap plus multiple shots on goal equals reset potential The chart is ugly. That is why the setup works if execution holds. You have revenue up roughly 33 percent in 2024 from the lab network, losses narrowing, Europe opening through Swissmedic approval, a live U.S. feasibility that sets …

Reimbursement is the unlock. Performance buys coverage Diagnostics do not scale without coverage. The math is harsh. Patients screen when payers pay. For CRC, the addressable pool is huge but adherence lags near 60 to 65 percent in the U.S. A test that pairs high sensitivity with patient friendly collection …

CRC screening is a massive market with a compliance gap you can drive a truck through Colorectal cancer is not niche. Globally it accounts for roughly 1.9 million new cases a year. In the U.S., it is about 150k new cases and around 50k deaths annually. Screening works, yet real-world …

Major European Push Underway for a Life-Saving Test! There's been a lot of talk lately about a small diagnostics company making big moves in Europe, and it looks like the chatter is for real. Why does this matter? Because we're talking about screening for Colorectal Cancer (CRC), a major problem …

MCED And AI Are Lifting The Whole Early Detection Trade Headlines around multi cancer blood tests and AI screening are everywhere. That helps targeted screens too, because payers and hospitals are already debating coverage, workflow, and economics. In that context, MYNZ sits as a focused CRC and pancreas platform rather …

Top 5 Event Calendar To Watch Over The Next Two Quarters SEQUA: U.S. commercialization for its medical pump is starting to show up in chatter. Near-term checks are first purchase orders, hospital onboarding pace, and gross margin in the next report. If reorders appear, the story upgrades. MYNZ: diagnostics name …

Top 3 Picks Fundamentals First: Real Ops And Data MYNZ has an operating wedge. It sells a CRC screen in Europe through partner labs and has pooled study metrics that matter to clinicians. CRC sensitivity about 92 percent, advanced adenomas 82 percent, and high grade dysplasia 95.8 percent. The U.S. …

A Simple Valuation Framework: What Would Close The Gap For A Microcap Screen You do not need a price target to build a view. Start with drivers that move a diagnostics multiple. Clinical proof at scale: MYNZ plans a pivotal around 15,000 patients across about 150 U.S. sites after a …

MCED Hype Helps, But Targeted Screens May Win First On Cost And Coverage Galleri headlines are everywhere again. Pathfinder-2 reported it detected about seven times more cancers than standard screenings, with around 70 percent of detected cancers lacking routine screening and about half found at stage I–II. Price sits near …

Europe’s 90 Percent Screening Goal: Why Policy Is A Tailwind For A Small Player The EU’s Beating Cancer Plan targets 90% CRC screening coverage in eligible citizens. That is a policy push, not a headline. It means systems are expected to expand programs and close gaps between countries. CRC remains …

Post-Abbott-Exact World: What A $23B CRC Deal Implies For Small Screens Abbott just agreed to acquire Exact Sciences for about $105 per share, roughly $21B equity value and about $23B including debt. That is a sector reset for colorectal screening platforms like Cologuard and Oncotype under one roof. It tells …

The U.S. Corridor Is Open: FDA And Medicare Already Pay For Noninvasive CRC This is no longer a what-if market. Shield, Guardant’s blood test, is FDA approved as a primary CRC screen for average-risk adults and meets Medicare coverage requirements. Exact’s next-gen Cologuard Plus is FDA approved and slated to …

Why A Partner-Lab Model Can Expand Fast: Margin Logic And Execution KPIs Instead of building a single mega lab, MYNZ sells ColoAlert as a kit and lets partner labs run it. That model is already live in Europe and newly cleared in the UK (registration Sept 2, 2025) and Switzerland …

Thermo Fisher’s Role: From Prototype To Plug-And-Play Kits That Any Lab Can Run MYNZ is aligning with Thermo Fisher Scientific to develop a next-generation, kitted version of ColoAlert that can run on widely deployed platforms. That shift matters for scale. A decentralized kit lowers capital needs, speeds validation across multiple …

ColoAlert In Plain English: How A PCR Stool DNA Test Competes In CRC Screening Here is what МYNZ actually sells. ColoAlert is a PCR-based multiplex stool DNA assay aimed at early colorectal cancer detection. It looks for molecular biomarkers in stool and is non invasive. Think of it as the …